Products

VPC 51299 | 857347

(R,E)-(3-palmitamido-4-(4-((4-(2,2,2-trifluoroethoxy)pyridin-2-yl)methoxy)phenyl)but-1-en-1-yl)phosphonic acid

857347P

Powder

857347P-
1mg
$210.00

All Prices in US Dollars
Quantity discounts may be available at the 5 and 10 count level.
Contact customer service for a quote.
Add your chosen unit to the shopping cart and adjust the quantity to see the discount.


To purchase larger quantities of this product please contact our Customer Service Department

  • Product
  • Data
  • Downloads
  • Reference
VPC51299 is a potent low micromolar inhibitor containing a vinyl phosphonate head group and possessing a half-life of approximately 90 min in rats when dosed intravenously. Previously developed LPA1/LPA3 receptor antagonists contain a labile phosphate head group which impairs evaluation of scaffold LPA receptor antagonists in vivo. VPC51299 has replaced the phosphate with a more stable head group while retaining potency at both LPA1 and LPA3 to facilitate future in vivo studies of the biological functions of these receptors. Refer: J.E. East, et al. (2011). Development of a phosphatase-resistant, L-tyrosine derived LPA1/LPA3 dual antagonist. Medchemcomm 2:325-330.This product is covered by Patent Number US 8,283,339 B2. Avanti manufactures this under license from University of Virginia.
Molecular Formula
C34H50 F3N2O6P
Percent Composition
C 60.88%, H 7.51%, F 8.50%, N 4.18%, O 14.31%, P 4.62%
Purity
>99%
Stability
1 Years
Storage
-20°C
Molecular Weight
670.740
Exact Mass
670.336
Download
Notes
GIF Graphics File. 
GIF Graphics File. 
MDL Molfile. 
CDX File. 
East, J.E., K.M. Carter, P.C. Kennedy, N.A. Schulte, M.L. Toews, K.R. Lynch, and T.L. Macdonald. (2011). Development of a phosphatase-resistant, L-tyrosine derived LPA1/LPA3 dual antagonist. Medchemcomm 2:325-330. [PubMed]